Updated results of the phase I BALLI-01 trial of UCART22 Process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by Cellectis Biologics, in patients with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL) Meeting Abstract
| Authors: | Jain, N.; Chevallier, P.; Liu, H. T.; Schiller, G. J.; Méar, J. B.; DeAngelo, D. J.; Curran, K. J.; Grupp, S.; Baruchel, A.; Balsat, M.; LaCroce, A.; Roudet, C.; Korngold, A. B.; Newhall, K. J.; Laille, E.; Lee, D. J.; Frattini, M. G.; Larson, R. A.; Boissel, N. |
| Abstract Title: | Updated results of the phase I BALLI-01 trial of UCART22 Process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by Cellectis Biologics, in patients with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4847 |
| Language: | English |
| ACCESSION: | WOS:001159900800048 |
| DOI: | 10.1182/blood-2023-187252 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
